Brought to you by 
Pfizer gets rights to Auxilium's Xiaflex; deal ends
10 Dec 2015
Executive Summary
Auxilium Pharmaceuticals (focused on the areas of urology, endocrinology, and orthopedics) has licensed Pfizer exclusive rights to develop and commercialize Xiaflex (clostridial collagenase for injection) for Dupuytren's contracture and Peyronie's disease in the EU and 19 other European and Eurasian countries.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer gets rights to Auxilium's Xiaflex; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice